BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29272782)

  • 21. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
    Homann N; Pauligk C; Luley K; Werner Kraus T; Bruch HP; Atmaca A; Noack F; Altmannsberger HM; Jäger E; Al-Batran SE
    Int J Cancer; 2012 Apr; 130(7):1706-13. PubMed ID: 21618509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma.
    Mahuron KM; Sullivan KM; Hernandez MC; Chen YJ; Chao J; Melstrom LG; Paz IB; Kim JY; Mannan R; Lin JL; Fong Y; Woo Y
    J Gastric Cancer; 2024 Jul; 24(3):267-279. PubMed ID: 38960886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
    Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
    Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma.
    Sisic L; Blank S; Nienhüser H; Haag GM; Jäger D; Bruckner T; Ott K; Schmidt T; Ulrich A
    Surg Oncol; 2020 Jun; 33():177-188. PubMed ID: 28684226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
    Haag GM; Byl A; Jäger D; Berger AK
    Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
    Bichev D; Treese C; von Winterfeld M; Breithaupt K; Dogan Y; Schmidt SC; Daum S; Thuss-Patience PC
    Oncology; 2015; 89(2):95-102. PubMed ID: 25823985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
    Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Briasoulis E; Fatouros M; Roukos DH
    Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical tumor staging of adenocarcinoma of the esophagus and esophagogastric junction.
    Turkington RC; Parkes E; Kennedy RD; Eatock MM; Harrison C; McCloskey P; Purcell C
    J Clin Oncol; 2015 Mar; 33(9):1088. PubMed ID: 25646194
    [No Abstract]   [Full Text] [Related]  

  • 37. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
    Runkel M; Verst R; Spiegelberg J; Fichtner-Feigl S; Hoeppner J; Glatz T
    BMC Surg; 2021 Jan; 21(1):35. PubMed ID: 33435947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
    Saunders JH; Bowman CR; Reece-Smith AM; Pang V; Dorrington MS; Mumtaz E; Soomro I; Kaye P; Madhusudan S; Parsons SL
    J Surg Oncol; 2017 Jun; 115(7):821-829. PubMed ID: 28257148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for Esophageal Adenocarcinoma.
    Lam KO; Kwong DLW
    Methods Mol Biol; 2018; 1756():19-34. PubMed ID: 29600357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.